Payment overview · 2025
General Payments
$565.19
32 reported records · 13 companies
Healthcare provider profile · identity verified
Robert J Vaschak, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SANDUSKY, OH · NPI 1336162288
Verified facts
What the public records show
CMS Open Payments records show Robert J Vaschak, D.O. received $565.19 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Creon, Eliquis, Fanapt, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 467 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 467 claims for Eliquis by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.14 | 30.6% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.52 | 14.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.16 | 10.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.40 | 6.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.79 | 6.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.74 | 6.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.56 | 5.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.11 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.16 | 3.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.72 | 3.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.68 | 2.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.52 | 2.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.69 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $565.19 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.32 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.32 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.16 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.33 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $50.51 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 19 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 467 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
467 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
139 | 78 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
467 | 54 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1101 | 269 |
| Levothyroxine Sodium | Levothyroxine Sodium | 641 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 555 | 147 |
| Eliquis | Apixaban | 467 | 54 |
| Losartan Potassium | Losartan Potassium | 432 | 126 |
| Lisinopril | Lisinopril | 400 | 101 |
| Omeprazole | Omeprazole | 348 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 101 |
| Sertraline Hcl | Sertraline Hcl | 305 | 57 |
| Gabapentin | Gabapentin | 303 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 77 |
| Metformin Hcl | Metformin Hcl | 268 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 57 |
| Spironolactone | Spironolactone | 214 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 41 |
| Ozempic | Semaglutide | 160 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 34 |
| Furosemide | Furosemide | 153 | 47 |
| Famotidine | Famotidine | 151 | 34 |
| Allopurinol | Allopurinol | 150 | 43 |
| Simvastatin | Simvastatin | 148 | 27 |
| Xarelto | Rivaroxaban | 142 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 139 | 78 |
| Carvedilol | Carvedilol | 135 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 31 |
| Potassium Chloride | Potassium Chloride | 130 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 31 |
| Jardiance | Empagliflozin | 118 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 26 |
| Prednisone | Prednisone | 115 | 47 |
| Aripiprazole | Aripiprazole | 113 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 27 |
| Torsemide | Torsemide | 102 | 29 |
| Memantine Hcl | Memantine Hcl | 100 | 17 |
| Donepezil Hcl | Donepezil Hcl | 98 | 20 |
| Buspirone Hcl | Buspirone Hcl | 91 | 15 |
| Atenolol | Atenolol | 87 | 22 |
| Alendronate Sodium | Alendronate Sodium | 85 | 22 |
| Baclofen | Baclofen | 83 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | suppressed |
| Risperidone | Risperidone | 78 | suppressed |
| Ezetimibe | Ezetimibe | 75 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 18 |
| Mirtazapine | Mirtazapine | 70 | 14 |
| Bupropion Xl | Bupropion Hcl | 66 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 34 |
| Chlorthalidone | Chlorthalidone | 65 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 20 |
| Farxiga | Dapagliflozin Propanediol | 63 | 15 |
| Metformin Hcl Er | Metformin Hcl | 61 | 29 |
| Montelukast Sodium | Montelukast Sodium | 60 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 17 |
| Celecoxib | Celecoxib | 57 | 20 |
| Sodium Chloride | Sodium Chloride Irrig Solution | 57 | suppressed |
| Estradiol | Estradiol | 53 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 17 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | 16 |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Mounjaro | Tirzepatide | 51 | 20 |
| Latanoprost | Latanoprost | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 49 | 12 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Lovastatin | Lovastatin | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 12 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | 12 |
| Humalog | Insulin Lispro | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | 11 |
| Valsartan | Valsartan | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 11 |
| Finasteride | Finasteride | 33 | 11 |
| Olanzapine | Olanzapine | 33 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Nyamyc | Nystatin | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 19 |
| Repaglinide | Repaglinide | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Multaq | Dronedarone Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 14 |
| Eplerenone | Eplerenone | 25 | suppressed |
| Fanapt | Iloperidone | 25 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 19 |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Aptiom | Eslicarbazepine Acetate | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Anastrozole | Anastrozole | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $565.19 · 32 records | ABBVIE INC. | ABRYSVO, AUSTEDO XR, COMIRNATY, CREON, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 3, LINZESS, MINIMED 780G, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, UNITHROID, VRAYLAR, Wegovy, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error